Procyon BioPharma Inc -
Procyon names Newman as VP and chief scientific officer
Procyon BioPharma Inc
PBP
Shares issued 43,217,544
Oct 11 2000 close $1.730
Oct 12 2000 9:29:21
Mr. Hans Mader reports
Procyon BioPharma has appointed Dr. Christopher E. Newman as
vice-president and chief scientific officer. Dr. Chandra Panchal,
co-founder and senior executive vice-president, who has acted as chief
scientific officer until this appointment, will now focus his energies on the
evaluation of new technologies for Procyon's in-licensing activities.
"We are very pleased to have been able to recruit someone of Dr.
Christopher Newman's calibre and experience for this senior position,"
said Hans J. Mader, Procyon's president and chief executive officer.
"His medical, research and clinical experience in oncology and disease
management, as well as his experience with the Food and Drug
Administration (FDA) drug approval process will be central to the
development of Procyon's core technologies and late-stage products."
Prior to his appointment as vice-president and chief scientific officer at
Procyon, Dr. Newman held several important senior medical and
industry positions including, head of the Oncology Clinical Science
Group at Quintiles, Europe, medical director and associate medical
director of disease management at Glaxo Wellcome Inc., and director of
clinical research at Abbott Pharmaceuticals Inc. Dr. Newman is also a
medical graduate from the University of Birmingham (United Kingdom)
and a fellow of the Royal College of Surgeons (London). He has
published over 60 articles in scientific and medical journals. His
experience in strategic consulting and preparation of clinical
development plans for new oncology products from the preclinical stage
through phase I and accelerated proof of concept, to phase III and
phase IV, will be of significant value to Procyon. His background has
provided an excellent preparation to head up Procyon's product
portfolio of cancer-related technologies and drugs including its two
leading-edge core technology platforms -- PSP(94) and ANA, as well
as its two late-stage products -- Colopath and Fibrostat. |
